Bead bed microfluidic device for testing mechanical embolization of shear-thinning hydrogels

Area of Science:

• Biomaterials Science
• Microfluidics
• Cancer Therapy

Background:

• Hepatocellular carcinoma (HCC) is a leading cause of cancer death globally.
• Current embolic agents for HCC lack precise delivery and effective testing models.
• Existing in vitro models fail to replicate the complex microenvironment of human capillary networks.

Purpose of the Study:

• To develop a novel bead-bed microfluidic device that emulates human capillary networks for evaluating embolic agents.
• To assess the performance of shear-thinning biomaterials (STBs) in a physiologically relevant microenvironment.
• To provide a scalable, non-animal testing platform for preclinical screening of embolic agents.

Main Methods:

• Fabrication of a microfluidic device using photocrosslinkable gelatin methacryloyl (GelMA) microbeads.
• Mimicking capillary-scale networks with interstitial voids between packed beads.
• Creating larger vessel pathways using annealed GelMA layers.
• Integrating cellular encapsulation for simultaneous embolization and cytotoxicity assessment.

Main Results:

• The bead-bed microfluidic device successfully emulates vascular complexity and capillary-scale networks.
• The platform allows for the assessment of embolization efficiency, flow behavior, and cell-targeting efficacy of embolic materials.
• Simultaneous evaluation of mechanical occlusion and biological response (cytotoxicity) was achieved.

Conclusions:

• The developed bead-bed microfluidic platform offers a versatile and scalable in vitro testing tool for embolic agents.
• This approach advances non-animal testing methodologies, aligning with FDA initiatives.
• The system provides a quantitative, biologically functional method for optimizing next-generation embolic materials for HCC treatment.